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1 Introduction 
1.1 Hepatocellular carcinoma 
1.1.1 Liver cells and the role of hepatic stellate cells for 
hepatic fibrosis and HCC progression 
The principal cell type found in the liver is the hepatocyte. Overall, hepatocytes 
represent approximately 94 vol. percent of the liver. The rest comprises various 
non-parenchymatic cells - Kupffer cells (resident liver macrophages), sinusoidal 
endothelial cells, liver lymphocytes and hepatic stellate cells (HSC). HSC in the 
normal liver are perisinusoidal cells of still uncertain embryological origin, 
responsible for the synthesis of basal membrane like-extracellular matrix (ECM), 
components of the subendothelial space of Disse and for storage and 
metabolism of vitamin A and retinoids (1). As HSC are less known outside the 
field of hepatology but are extensively used in the present work, their crucial role 
in liver disease is to be shortly explained. 
Activation of HSC, following liver injury, progresses in sequential stages of 
initiation and perpetuation (2). Initiation is an early response stimulated by a 
number of paracrine signals, leading to a transient and potentially reversible 
contractile and profibrogenic phenotype, characterized by rapid induction of 
certain growth factor receptors and consequently increased responsiveness to 
growth factors and mediators, which are responsible for eliciting phenotypic 
responses operated by fully activated myofibroblast (MF)-like phenotype 
(perpetuation). These include most notably enhanced proliferation, 
migration/chemotaxis, contractility, excess deposition and altered remodeling of 
ECM (3). 
The accumulation of ECM proteins in progressive liver fibrosis alters the hepatic 
architecture by forming a fibrous scar, and the subsequent development of 
nodules of regenerating hepatocytes defines cirrhosis. Cirrhosis causes 
hepatocellular dysfunction and increased intrahepatic resistance to blood flow. 
The consequences are hepatic insufficiency and portal hypertension (4). 
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Ultimately, cirrhosis leads to a clinically overt loss of liver function 
(decompensated cirrhosis), and most importantly, liver cirrhosis is the main risk 
factor for the development of hepatocellular carcinoma (HCC) (5). 
Thus, activated HSC are a driving force of liver fibrosis progression and 
consequently of origination of HCC. However, once HCC develops, HSC also 
play a direct role in tumor progression. They are able to infiltrate the HCC stroma 
and as shown by a recent study, HSC promote HCC growth and invasiveness 
and diminish central necrosis in vitro and in vivo probably via activation of 
nuclear factor kappa B (NFκB) and extracellular-regulated kinase (ERK) in HCC 
cells, two signaling cascades that play a crucial role in HCC progression (6). 
1.1.2 Epidemiology of HCC 
1.1.2.1 Incidence and regional differences in etiology of HCC 
Hepatocellular carcinoma (HCC) is the most common form of primary liver 
cancer with 85-90% (7). There are considerable differences in HCC incidence 
around the world.  
The highest incidence rates are reported from China (46 per 100,000 population 
per year, total annual incidence of 137,000 cases. The rest of Eastern Asia and 
most of Africa are also high-endemic regions with incidence rates of 35.5 and 
24.2, respectively. Regions of intermediate incidence areas include several 
countries in Eastern and Western Europe, Thailand, Indonesia, Jamaica, Haiti, 
New Zealand and Alaska. North and South America, most of Europe, Australia 
and parts of the Middle East are low incidence areas with less than 3/100,000 
cases per year (7). 
These marked differences are explained by studying the various etiological 
factors for HCC development and their regional distribution. The regional 
differences in HCC incidence mostly reflect the different incidence of chronic 
infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) (8). In most of the 
Asia-Pacific regions as well as in Africa endemic HBV is the most important 
etiological factor, with the notable exception of Japan, where HCV is by far the 
most common risk factor. Within Europe there are also differences in regard to 
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etiology. In Southern Europe viral etiology accounts for as much as 76% of HCC 
cases (9)  while in Central and Northern Europe HBV and/or HCV infections are 
present in only about half of patients (10;11). The fact that within a single country 
there may be regional and ethnic differences in HCC incidence patterns further 
adds to the considerable intra- and international variability of HCC etiology (12). 
1.1.2.2 Risk factors  
In the vast majority (70-90% according to region) of cases HCC develops in a 
cirrhotic liver. Thus, all causes for liver cirrhosis can be considered as separate 
risk factors for HCC. This differentiation is important because the cause of liver 
cirrhosis significantly affects the associated risk to develop HCC, 
clinicopathological tumor features, the choice of treatment, and consequently the 
prognosis (13). 
It should be noted that all factors that can lead to HCC development in the setting 
of liver cirrhosis can do so in the absence of cirrhosis if the level of hepatocellular 
toxicity necessary to lead to liver cirrhosis is not yet reached, but the 
carcinogenic effect is already strong enough to induce HCC (14). 
• HBV 
The single most common HCC risk factor is hepatitis B virus (HBV) infection 
responsible for > 60 % of all cases worldwide. The hepatocarcinogenic potential 
of HBV is evidenced by a multitude of clinical studies with an overall odds ratio 
(OR) of up to 48 in a study from India (15). Major factors in HBV-induced 
hepatocarcinogenesis are chronic inflammation and the effects of cytokines in 
the development of fibrosis and liver cell proliferation, further, the role of 
integration of HBV DNA into host cellular DNA, which, in some situations, acts to 
disrupt or promote expression of cellular genes that are important in cell growth 
and differentiation. In addition, expression of HBV proteins may have a direct 
effect on cellular functions, and some of these gene products can favor malignant 
transformation (16). 
The risk of developing HCC upon HBV infection varies greatly and is influenced 
by host as well as viral-related factors in addition to external or environmental 
factors.  Some of the most important include an advanced stage of the disease, 
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longer duration of cirrhosis, the activity of the underlying hepatitis and high HBV 
load (17;18). Further, HBV genotype, specific alleles and mutations in the viral 
basal core promoter are associated with an increased risk to develop HCC (19-
21). 
• HCV 
Worldwide, HCV infection is the second most common etiological factor for HCC. 
The overall odds ratio is estimated to be 17 (22). The oncogenic process of HCV 
infection itself, which probably requires multiple steps of genetic alterations as 
result of virus-specific and virus-non-specific immune responses, and probably a 
direct cytopathic effect of HCV itself is still poorly understood (23;24). 
As acute HCV infection often remains undetected it is difficult to determine 
whether longer duration of HCV infection plays a role as observed in HBV. In 
contrast to HBV infection, the HCV genotype or the viral load are no major 
factors for the course of the disease (5). A higher degree of fibrosis, male gender 
and the presence of co-risk factors such as alcohol and concomitant HBV 
infection increase the risk of developing HCC due to HCV infection (25;26). 
• Alcohol 
In Western Europe, high consumption of alcohol is one of the major risk factors 
for developing liver cirrhosis. The risk of developing alcohol-related HCC 
depends largely on the quantity of alcohol consumption. Overall, alcohol 
consumption is associated with a 2-fold increase of the individual risk for HCC 
development, but in cases of > 80 g day this increases to a 6-fold risk (27;28). 
Proposed mechanisms for the hepatocarcinogenic properties of alcohol include 
the chronic inflammation that leads to stimulation of apoptosis and through 
enhanced cell injury to an increased cellular proliferation and hyperregeneration. 
Further, inflammation increases oxidative stress that may cause DNA damage.  
Another important mechanism involves the presence of toxic metabolites like 
acetaldehyde capable of binding to the DNA, consequently leading to constant 
genomic alterations and interference with DNA-repair enzymes (29). The high 
levels of acetaldehyde also lead to a decreased antioxidant response, e.g. by 
binding of glutathione and reduction of the mitochondrial glutathione content 
causing mitochondrial dysfunction, lipid peroxidation and impairment of the 
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cellular tumor necrosis factor (TNF) tolerance (30). All these mechanisms are 
supported by general alimentary deficiency for vitamins and supplementary 
factors like folic acid and retinol in case of chronic alcohol abuse (31;32). 
• Obesity and NAFLD  
Epidemiological studies have shown that obesity is a risk factor for hepatocellular 
carcinoma (33). The relationship between obesity and non-alcoholic fatty liver 
disease (NAFLD) is well established, and case reports have shown progression 
of NAFLD to cirrhosis and hepatocellular carcinoma (34-36). Although no study 
has clearly tied all of these variables together, it is likely that the association of 
hepatocellular carcinoma with obesity represents the progression of underlying 
NAFLD to cirrhosis (33). Putative oncogenic mechanisms are the initiation by 
lipid peroxidation and free radical oxidative stress, compensatory proliferation   of 
small oval progenitor cells , fat-induced up-regulation of anti-apoptotic factors, 
alterations in growth factors and cytokines e.g. transforming growth factor (TGF) 
and tumor necrosis factor (TNF), stimulating oval cell proliferation (37-39). 
Moreover, lipid peroxidation encourages the development of cancer-promoting 
mutations e.g. mutations of the p53 tumor suppressor gene seem to be 
potentiated by the 4-hydroxynonenal aldehyde, a product of omega-6 fatty acid 
peroxidation (40).  
With the growing worldwide obesity epidemic this risk factor is likely to gain more 
significance in the future. 
• Hemochromatosis and iron metabolism 
In hereditary hemochromatosis the hepatotoxic effects of iron overload can lead 
to progressive fibrosis and eventually cirrhosis and HCC (41). As some cases of 
HCC have occurred in non-cirrhotic patients with hematochromatosis, a direct 
role for iron in carcinogenesis has been suggested (42;43). The latter has been 
supported by animal studies, where pre-neoplastic nodules and even HCC in the 
absence of fibrosis developed in rats fed a high-iron diet (44;45). The molecular 
mechanisms involve epigenetic alterations of genes characteristically 
hypermethylated in HCC, suggesting that epigenetic changes due to iron loading 
are an early event in hereditary hemochromatosis, and may lead to the increased 
risk of progression to HCC (46). 
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• Rare risk factors for HCC 
Other rare causes of HCC include autoimmune hepatitis, chronic dietary intake of 
aflatoxine, metabolic disorders (e.g. alpha antitrypsine deficiency, glycogenosis 
Type I), biliary diseases (e.g. primary biliary sclerosis), certain hepatotoxic 
medications (e.g. anabolic steroids) and others. 
1.1.2.3 Frequency of HCC risk factors  - an example from a German 
university hospital 
The human HCC samples used in this work originate from the largest 
consecutive HCC patient series in Germany at the University Hospital 
Regensburg. Figure 1 gives the relative contribution of major etiologic factors for 
the development of HCC for this cohort. 
Hemochromatosis 
and others
3%
Cryptogenic 
cirrhosis
6%
No risk factors, no 
cirrhosis
3%
Hepatitis B
8%
Hepatitis B and 
hepatitis C
1%
Hepatitis C
16%
Alcohol
58%
Alcohol and viral 
hepatitis 
5%
 
Figure 1: Etiology of underlying liver disease of HCC patients. Data are 
depicted of 374 patients. 
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1.1.3 Therapy of HCC  
The therapeutic options for HCC fall into five main categories: (1) surgical 
interventions, including tumor resection and liver transplantation, (2) 
percutaneous interventions, including ethanol injection and radiofrequency 
thermal ablation, (3) transarterial interventions, including embolization and 
chemoembolization, (4) radiation therapy, and (5) drugs as well as gene and 
immune therapies (47). Curative treatment modalities are still the sole domain of 
surgery and comprise partial hepatectomy and liver transplantation (48). Liver 
transplantation is the ideal treatment for early HCC because both the malignant 
tumor and diseased liver can be eradicated by this treatment (49). However, 
because of organ shortage or continued alcohol abuse it cannot be performed 
often (50). Hepatectomy can be performed in timely fashion with less technical 
difficulty, but the risk of HCC recurrence is higher, even though 5-year survival in 
patients who meet certain criteria is the same as that with liver transplantation 
(51). 
Therapy N (%) 
resection 124 (27.1%) 
best supportive care (no specific therapy) 93 (20.3%) 
local ablative therapy (TACE, RFA) 93 (20.3%) 
chemotherapy alone 50 (10.9%) 
liver transplantation 36 (7.9%) 
chemotherapy and at least one ablative therapy 20 (4.4%) 
multiple resections 11 (2.4%) 
therapy with thymophysin  9 (2.0%) 
combination of various ablative therapies 8 (1.7%) 
percutaneous ethanol injection alone 7 (1.5%) 
resection followed by liver transplantation 7 (1.5%) 
 
Table 1: Frequency of HCC therapeutic modalities at the University Hospital 
Regensburg 
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Notable palliative options that have been shown to prolong survival include 
radiofrequency thermal ablation (RFA) and transarterial chemoembolization 
(TACE) (47). 
Finally, patients who are at a very advanced stage of disease when no benefit is 
to be expected by any specific treatment typically receive so called “best 
supportive care” which generally comprises symptom-oriented treatment with e.g. 
analgesic drugs, antibiotics, transfusions and others as appropriate in each 
individual case. Table 1 summarizes the treatment options for HCC at the 
University Hospital  Regensburg. 
1.1.4 Prognosis of HCC 
Despite new therapies and attempts at early detection, HCC remains a disease 
with a very high mortality, a yearly fatality ratio close to 1 and in relation to other 
types of cancer an especially poor prognosis (52). This is illustrated by the fact 
that worldwide HCC has the 5th highest cancer incidence but the 3rd highest 
cancer mortality (52). In Europe, which is considered a low-endemic area, HCC 
was estimated to be the 14th most common cancer in 2006 but had the 7th 
highest mortality (53).   
Overall survival of the largest consecutive German series of HCC patients, a 
source of HCC tumor samples used in this work, is shown in Figure 2.     
Corresponding survival rates are given in Table 2. 
In general, there is considerable variation in survival rates reported in different 
studies. Thus, consecutive clinical series in low-endemic regions as Austria (10)  
or the United States (54) lie in the 2-10 months range, while other consecutive 
studies from Turkey (55) and Portugal (56) report between 17 and 24 month 
survival rates. The highest overall median HCC survival rates are found in 
studies of “selected“ HCC populations e.g. in an Italian study (25.7 months) of 
“early-intermediate” tumors identified in a HCC prevention program (57), and in 
Taiwan (26.8 months) in a cohort of patients undergoing hepatic resection (58). 
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Figure 2:  Kaplan-Meier survival curve of HCC patients. Data 
reflect 458 consecutive patients with HCC, both treated and 
untreated. Median survival was 19 months (95% CI: 15.3-22.7). 
 
 
 
Survival rate at Percentage of patients living 
1-year after diagnosis 59 % 
2-years after diagnosis 45 % 
3-years after diagnosis 30 % 
4-years after diagnosis 21 % 
5-years after diagnosis 16 % 
 
Table 2:  1-, 2-, 3-, 4- and 5- year survival rates of HCC 
patients at the University Hospital Regensburg 
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1.2 Methylthioadenosine phosphorylase (MTAP) and  
methylthioadenosine (MTA)  
The molecular pathogenesis of HCC is not well understood. Studies have 
described many genomic aberrations and epigenetic modifications in gene 
expression in HCC but the relative importance and the precise role in the 
sequence of disease progression of many of these abnormalities are still to be 
elucidated (59;60). Methylthioadenosione phosphorylase (MTAP or 5´-deoxy- 5´-
methylthioadenosine orthophosphate methylthio-ribosyltraexpressionnsferase) is 
one of the genes that has recently been implicated in HCC progression (61;62). 
1.2.1  The human  MTAP gene 
The human MTAP gene (EC 2.4.2.28) resides on the short arm of chromosome 
9, in the chromosomal region 9p21, from 21792543 to 22111094 (5´? 3´). It 
consists of eight exons and seven introns (Figure 3).  
 
Figure 3: Intron-Exon structure of the human MTAP gene. Modified from (63) 
 
Exon 1 encodes 11 amino acids and the 5' noncoding region, the sizes of exons 
2-7 range from 79 to 240 bp. The last (8th) exon encodes the C-terminal 12 
amino acids and the 3' noncoding region (63).  
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Biochemical and structural evidence indicate that human (and mammalian) 
MTAP protein is a trimer consisting of three identical subunits of 32 kDa that in 
humans contain 283 amino acid residues (64). 
1.2.2 Functions of MTAP 
MTAP catalyzes the phosphorylation of 5´-deoxy-5´-(methylthio)adenosine (MTA) 
which is formed as a by-product of polyamine synthesis to yield adenine and 
methylthioribose-1-phosphate (MTR-1P), (Figure 4). 
 
. 
Figure 4: Schematic presentation of the MTAP metabolic 
pathway. Modified from (65) 
 
Adenine is used to replenish the AMP and ATP pools while MTR-1P is converted 
in a series of reaction to regain methionine (66;67).. Notably, MTAP is the rate-
limiting step in these salvage pathways. 
Besides its role in regaining adenine and methionine, MTAP is important for the 
proper functioning of polyamine metabolism. Loss of MTAP has been shown to 
cause a significant decrease in intracellular polyamine levels and alters the ratio 
of putrescine to total polyamines in vitro (68). The mechanism involves the 
accumulation of MTAP´s substrate, methylthioadenosine (MTA) which in higher 
concentrations acts as a potent inhibitor of spermine and spermidine synthase, 
two key enzymes of the polyamine synthetic pathway (69). 
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1.2.3 MTAP expression in normal and cancerous cells and 
tissues 
Given the fundamental role of MTAP in the cellular processes outlined above, it 
is not surprising that MTAP is abundantly expressed in a wide range of healthy 
cells and tissues (70). Baseline MTAP expression in the liver is relatively high in 
comparison to other organs, which can be explained by the key role of the liver in 
methionine metabolism (71). 
However, in cancer, MTAP expression abnormalities have been described by 
many studies. These are caused by both genomic and epigenetic changes. 
Partial or complete deletions of MTAP are quite frequent in a wide range of 
tumors including leukaemia (72), lung cancer (73),   pancreatic adenocarcinoma 
(74;75), osteosarcoma (76), endometrial cancer (77). In contrast, epigenetic 
mechanisms are responsible for MTAP downregulation in melanoma and HCC 
(62;78) as well as lymphoma (79). However, MTAP may also be up-regulated in 
cancer as shown by a recent study in human colon carcinoma (80). 
Generally, by far the most common MTAP abnormality in cancer remains a 
deletion of MTAP gene. This can be explained by the location of the MTAP gene 
in the 9p21 chromosomal region which exhibits frequent deletions in a variety of 
human malignancies.  This region contains, starting from the centromeric end, 
the genes p15—p16—MTAP—IFN-a—IFN-b (70). The former two genes encode 
for two cyclin-dependent kinase inhibitors which are recognized tumor 
suppressor genes (81). Co-deletions of MTAP and one or more of these genes 
are common (82;83), and the co-deletion frequencies vary between 35 and 70 % 
depending on the kind of tumor (65). This raises the question whether the 
observed MTAP deficiency in cancer has any relevant cancer-promoting effect 
on its own or is an associated feature of p15 and p16 tumor suppressor 
deletions. 
One argument in favour of a unique tumor-promoting role of MTAP deficiency 
was the finding that loss of MTAP activity results in the activation of ornithine 
decarboxylase (ODC). This effect is probably mediated by 2-keto-4-
methylthiobutyrate (MTOB) an intermediate in the methionine salvage pathway 
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(69). Elevated ODC activity is long recognized for its cancer-promoting effect in-
vitro and in vivo (84;85). Further, in HCC ODC activity was shown to be 
correlated with the degree of malignancy (86;87). 
Another relevant contribution suggesting a unique tumor-promoting role of MTAP 
deficiency was the discovery that MTAP deficiency results in higher MTA 
concentrations in vivo in melanoma and that MTA induces a number of pro-
tumorigenic effects e.g. increased migration of cancer cells (88). 
1.2.4 Clinical implications of MTAP deficiency for cancer 
therapy  
After it was clear that MTAP is absent in a high percentage of tumors much of the 
research has focused on the possibilities to exploit this therapeutically. Initial 
experiments showed that inhibitors of de novo purine synthesis, methotrexate or 
azaserine, which are very commonly used chemotherapeutic agents, in 
combination with MTA, selectively killed MTAP-negative cells, while sparing 
MTAP-positive cells as the latter could derive their purine nucleotide 
requirements from MTA (89). A number of studies that followed up on this 
proposal examined other inhibitors of de novo purine synthesis, such as 5,10-
dideazotetrahydrofolate and L-alanosine, an inhibitor of AMP synthesis from IMP 
(90). 
Based on this promising in-vitro data several Phase I and II clinical trials with L-
alanosin were started, however the treatment was considered ineffective (91;92). 
In a different approach, it was proposed that if serum were depleted of 
methionine by a methioninase, normal cells, but not MTAP-negative tumor cells, 
could be rescued by providing MTA, which is cleaved to MTR-1-P and leads to 
methionine synthesis (93). To the best of our knowledge, there have been no 
reported clinical trials of this proposed therapy. 
Finally, a very recent study suggested a combination therapy of  MTA and a toxic 
adenine analog, e.g. 2-fluoroadenine (65). In MTAP-positive cells, abundant 
adenine, generated from supplied MTA, competitively blocks the conversion of 
an analog by adenine phosphoribosyltransferase (APRT), to its active nucleotide 
form. In MTAP-negative tumor cells, the supplied MTA cannot generate adenine; 
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hence conversion of the analog is not blocked. The study found that this 
combination therapy is effective in MTAP-deficient human breast and lung cancer 
cell lines, while fibroblasts expressing MTAP were protected (65). 
1.2.5 Regulation of MTAP  
Data on the regulation of MTAP are rather scarce and inconclusive. 
As explained above, in most cases the loss of MTAP activity or mRNA is the 
result of homozygous deletions of the MTAP gene. The presence of a CpG island 
proximal to the transcription start site of the MTAP promoter suggests a 
transcriptional regulation of the gene through a methylation/demethylation 
mechanism (78). 
This notion was confirmed in HCC (hepatocellular carcinoma) cell lines showing 
down-regulation of MTAP gene expression that could not be attributed to 
genomic losses or mutations but to promoter hypermethylation (62). As already 
mentioned, this mechanism is also present in a share of melanomas and 
lymphomas (78;79). 
Additionally, it has been found that the transcriptional activation of the human 
MTAP gene is mediated by the binding of the CCAAT binding factor to a distal 
CCAAT motif in the promoter (94).  
Besides the regulation at the transcriptional level, there is also evidence 
suggesting modulation of MTAP activity. Phosphorylation of Ser183 and Thr188 
residues have been recently reported, although the biological significance of 
these modifications must be demonstrated (95). 
Oxidation also arises as a mechanism to modulate MTAP activity as suggested 
by the requirement of the enzyme for thiol-reducing agents and its specific and 
rapid inactivation by thiol-blocking groups (96). 
1.2.6 5´-Methylthioadenosine – a key player at a biochemical 
crossroads 
It is plausible that alterations in MTAP activity as described in cancer may be 
associated with altered levels of MTAP´s substrate, 5´-methylthioadenosine 
(MTA). This was confirmed for melanoma cell lines and tissues where higher 
 
 15
MTA levels induced a number of pro-tumorigenic changes in melanoma cells 
(88).  
The natural existence of MTA has been known for almost a century now (66) and 
its molecular structure was reported in 1924 (71). 
MTA is a hydrophobic sulfur-containing adenine nucleoside in which the hydroxyl 
group in the 5´ position of the ribose is substituted by a methylthio moiety (Figure 
5). This methylthio moiety is derived from the amino acid methionine, while the 
rest of the molecule comes from ATP. 
 
 
 
Figure 5: Structure of 5´-methylthioadenosine (MTA). 
 
The major source of MTA is, as mentioned, polyamine biosynthesis which occurs 
in all mammalian cells, and starts with the decarboxylation of S-
adenosylmethionine (SAM) by the enzyme SAM decarboxylase (SAMDC) 
(Figure 6). Decarboxylated SAM (dSAM) is the immediate precursor of MTA. It is 
a substrate for the aminopropyltransferases. These enzymes transfer the 
aminopropyl group of dSAM to putrescine forming spermidine (spermidine 
synthase), and subsequently to spermidine forming spermine (spermine 
synthase), with MTA forming as a “by-product“ in both reactions. 
MTA is metabolized by MTAP to adenine and 5-methylthioribose-1-phosphate 
(MTR-1P). Adenine is needed to ultimately replenish the AMP and ATP pools 
while MTR-1P undergoes a complex set of oxidations to give 2-keto-4-
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methylthiobutyrate (MTOB), which is finally transaminated to methionine. 
Consequently, the two metabolites from which SAM and MTA are formed, 
namely methionine and ATP, are thus recovered (66;71) 
As polyamine synthesis is a vital ubiquitous cellular process and since MTA is 
mainly produced during polyamine synthesis it is not surprising that MTA is found 
in small amounts in all mammalian tissues (and also in prokaryotes, yeast, plants 
and higher eukaryotes) (97). 
 
 
Figure 6: Methionine salvage and polyamine synthesis pathways. MTA is located at 
their crossroads forming as a by-product of the latter and being the initial substrate of the 
former. Enzymes are shown in italics; SAM, S-adenosylmethionine; SAMDC, S-
adenosylmethionine decarboxylase, ODC, ornithine decarboxylase. Modified from (69). 
 
1.2.7 Biological effects of MTA 
MTA has notable influence on fundamental cellular functions. Earlier studies 
have focused on MTA effects on lymphocytes showing that MTA inhibits several 
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lymphocyte functions. Mitogen-stimulated activation of murine and human 
lymphocytes (98;99), lymphocyte-mediated cytolysis (100) and natural killer cell 
mediated cytotoxicity (66) are strongly inhibited by high (>1000 µM) 
concentrations of MTA. A later study showed that in a murine pre-B cell line MTA 
at a concentration of 2000 µM impairs LPS induced NFkB signaling (101). 
There are convincing studies that MTA inhibits spermine synthase and to a 
lesser extent spermidine synthase and ODC (97;102).  
More arguable are effects regarding some tumor-related cellular functions. 
Depending on the type of cell analyzed, and the MTA concentration used, studies 
describe various, partly opposite effects 
In cultured melanoma cell lines for example, exogenous addition of 50-100 µM 
MTA caused up-regulation of tumor-promoting genes and enhanced 
invasiveness and vasculogenic mimicry while no similar genes up-regulation was 
observed in normal melanocytes (88).  
However, decreased rather than increased invasiveness induced by MTA were 
suggested another study examining two rat ascites hepatoma cell lines, possibly 
due to alterations in the phospholipid composition and fluidity of the tumor cell 
membranes (103).  
MTA effects on apoptosis are another controversial issue. A recent study 
observed that SAM as well as MTA at a concentration of 4000 µM protected rat 
hepatocytes from okadaic-acid induced apoptosis (104). However, at a lower 
concentration, MTA induced apoptosis in the human HCC cell lines Huh7 and 
HepG2. It is unclear whether this represents a differential effect on normal vs. 
malignant cells as cells originated from different species (murine vs. human) and 
different concentrations were used. 
1.3  Aim of thesis 
Based on previous in vitro and in vivo studies in our group (62) suggesting 
functional role of MTAP in HCC progression this work aimed to  
(1) expand this analysis to human HCC tissue and establish associations of 
MTAP down-regulation with clinicopathological features of HCC tumors 
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(2)  examine whether MTAP expression correlates with MTA concentrations 
in human liver cell lines and tissues 
(3) elucidate the molecular mechanism of the tumor-promoting role of MTAP 
deficiency by analyzing the effects of MTA on tumor cells and their 
microenvironment. 
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2 Materials and Methods 
2.1 Chemicals and reagents 
Agarose SeaKem® LE Biozym, Hess/Oldendorf, Germany 
β-Mercaptoethanol Sigma, Deisenhofen, Germany 
DMEM medium PAA Laboratories, Cölbe, Germany 
DMSO Sigma, Deisenhofen, Germany 
FCS (fetal calf serum) PAN-Biotech, Aidenbach, Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
Penicillin Invitrogen, Karlsruhe, Germany 
Streptomycin Invitrogen, Karlsruhe, Germany 
Trypsin/EDTA PAA Laboratories, Cölbe, Germany 
 
All chemicals not listed were purchased at VWR (Darmstadt, Germany). 
 
2.2 Laboratory expendables 
CryoTube vials Nunc, Roskilde, Denmark 
Pipet tips  
(10, 20, 100 und 1000 μl) 
Eppendorf, Hamburg, Germany 
Falcon tubes (50 ml) Corning, New York, USA 
glassware (various) Schott, Mainz, Germany 
Multiwell plates Corning, New York, USA 
Pipettes (stripettes®) (5, 10, 25, 50 ml) Corning, New York, USA 
Reaction vessels (1.5 and 2 ml) Eppendorf, Hamburg, Germany 
Stripe tubes (0.2 ml) Peqlab, Erlangen , Germany 
Cell culture flasks T25, T75, T175 Corning, New York, USA 
 
 
 
 20
2.3 Laboratory instruments 
Heating block:
Thermomixer comfort  
 
Eppendorf, Hamburg, Germany 
PCR-cycler: 
GeneAmp® PCR System 9700 
 
Applied Biosystems, Foster City, USA 
Pipettes: 
Gilson (P2, P20, P200, P1000) 
 
Gilson, Bad Camberg, Germany 
Pipette controllers:  
Accu-jet®
 
Brand, Wertheim, Germany 
Shaking devices: 
KS 260 Basic Orbital Shaker  
 
IKA® Werke, Staufen, Germany 
Power Supplies:
Consort E145 
Power Supply-EPS 301 
 
Peqlab, Erlangen, Germany 
Amersham Biosiences, Munich, Germany 
Spectrophotometer: 
EMax® Microplate Reader 
SPECTRAFluor Plus  
    Microplate Reader  
 
MWG Biotech, Ebersberg, Germany 
Tecan, Männedorf, Switzerland 
Scale: 
MC1 Laboratory LC 620 D 
 
Sartorius, Göttingen, Germany 
Water bath: 
Haake W13/C10 
 
Thermo Fisher Scientific, Karlsruhe, Germany
Centrifuge: 
Biofuge fresco 
Megafuge 1.0 R  
 
Heraeus, Hanau , Germany 
Heraeus, Hanau, Germany 
Microscope: 
Olympus CKX41 with 
ALTRA20 soft imaging system 
 
 
Olympus Hamburg, Germany 
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2.4 Buffers 
PBS-Puffer 
 
140 mM NaCl 
10 mM KCl 
6.4 mM Na2HPO4
2 mM   KH2PO4   pH 7.4
 
TE-Puffer 
 
10 mM  Tris/HCl 
1 mM   EDTA   pH 8.0
2.5 Cell Culture 
2.5.1  Cell culture medium 
DMEM (high glucose/10%FCS) 4.5 g/l  Glucose  
300 µg/ml  L-Glutamine 
Supplemented with: 
10% (v/v) FCS  
400 U/ml  Penicillin  
50 µg/ml  Streptomycin 
 
HSC medium DMEM (high glucose/10%FCS) 
Supplemented with: 
10 µg/ml  Diflucan  
4 µg/ml  Ciprobay  
 
 
2.5.2 Cultivation of cell lines 
All cell culture work was conducted within a laminar flow biosafety cabinet (Hera 
Safe, Heraeus, Osterode, Germany). The cells were cultivated in a Binder series 
CB incubator (Binder, Tuttlingen, Germany) in 10% CO2 atmosphere at 37 °C. 
DMEM containing 4.5 g/l glucose and 300 µg/ml L-glutamine supplemented with 
 
 22
10% (v/v) FCS, 400 U/l penicillin and 50 µg/ml streptomycin was used as cell 
culture medium. For cell passaging adherent cells were washed with PBS and 
detached with trypsin (0.05%)/EDTA (0.02%) (PAA Laboratories, Cölbe, 
Germany) at 37 °C. Trypsination was stopped by addition of DMEM containing 
10% FCS. Subsequently, cells were centrifuged at 500 g for 5 min, and the 
obtained cell pellet was resuspended in fresh culture medium and distributed to 
new cell culture flasks achieving a cell density thinning factor of 5 to 10. Medium 
change took place every second day. Cell growth and morphology were 
controlled and documented with a microscope. Cell culture waste was autoclaved 
before disposal with a Sanoclav autoclave (Wolf, Geislingen, Germany). 
2.5.3 Human hepatocellular carcinoma cell lines 
The hepatocellular carcinoma cell lines PLC (ATCC CRL-8024) HepG2 
(ATCC HB-8065) and Huh7 (JCR B0403) were obtained from the American Type 
Culture Collection (ATCC) and the Japanese Collection of Research Biosources 
(JCRB), respectively. 
2.5.4 Isolation of primary human hepatocytes 
Primary human hepatocytes (PHH) were isolated in co-operation with the Center 
for Liver Cell Research (Department of Surgery, University of Regensburg, 
Germany) from human liver resections using a modified two-step 
EGTA/collagenase perfusion procedure (105-109). The experimental procedures 
were performed according to the guidelines of the charitable state controlled 
foundation HTCR, with the informed patient's consent. For cell isolation only 
tissue which has been classified as not pathological after macroscopical and 
microscopical investigation was used. All used liver resections have been 
negatively tested for HBV, HCV and HIV infection. Viability of the isolated 
hepatocytes was determined by trypan blue exclusion, and cells with viability 
greater than 85% were used for further tests. 
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2.5.5 Isolation of human hepatic stellate cells 
Human hepatic stellate cells (HSC) were isolated in co-operation with the Center 
for Liver Cell Research (Department of Surgery, University of Regensburg, 
Germany). After perfusion and separation of hepatocytes by an initial 
centrifugation step at 50 g (5 min, 4 °C) the supernatant containing the non-
parenchymal cells was centrifuged at 700 g for 7 min (4 °C). The obtained cell 
pellet was resuspended in HSC medium, and cells were seeded into T75 flasks. 
Within the first week, the medium was replaced daily. From the second week on 
medium change took place every 2-3 days. By cultivation on uncoated plastic 
HSC activate within the first 2 weeks and transdifferentiate to myofibroblast-like 
cells. Liver disease mediated HSC activation can be simulated in vitro that way. 
After 2 weeks the cell culture was split 1:3 by incubating the cells with 
Trypsin (0.05%)/EDTA (0.02%) solution. Thereby, only HSC detach, whereas 
Kupffer cells remain adherent to the plastic surface. Therefore, after the first 
passage only activated HSC remain in the cell culture which was confirmed by 
previously done analysis (110). 
2.5.6 Determination of cell number and viability 
Cell number and viability was determined by trypan blue exclusion test. The cell 
suspension was diluted 1:2 with trypan blue solution (Sigma, Deisenhofen, 
Germany) and applied on a Neubauer hemocytometer (Marienfeld GmbH, 
Lauda-Königshofen, Germany). Cells with impaired cell membrane integrity are 
stained blue, and therefore, can be clearly distinguished from intact cells which 
appear white under microscopic inspection. The cell number could be calculated  
after counting cells in all four quadrants of the hemocytometer, each containing 
sixteen smaller squares, with the following equation: 
Cell number/ml = Z x DF x 104 ÷ 4 
 Z = counted cell number in all four quadrants 
 DF = dilution factor (in the described procedure the factor is 2) 
The ratio of viable cells could be determined by setting the number of unstained 
cells in relation to the total cell number (blue und unstained cells). 
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2.5.7 Transfection of PLC cells with MTAP siRNA 
MTAP siRNAa (numbered 1, 2, 3 and 4), negative control siRNA and HiPerFect 
Transfection Reagent® were purchased from Qiagen (Hilden, Germany).  
Transfection of PLC cells was performed after the Qiagen fast-forward siRNA 
transfection protocol.  
Shortly before transfection, 200,000 cells per well were seeded on a 6-well plate 
in 2,300 μl of DMEM culture medium containing 10 % fetal calf serum. 150 ng 
siRNA per well was diluted in 100 μl DMEM without serum and 12 μl of HiPerFect 
Transfection Reagent was added to the diluted siRNA and mixed by vortexing. 
The samples were incubated for 10 min at room temperature to allow the 
formation of transfection complexes which were then added drop-wise onto the 
cells. The plates were gently swirled to ensure uniform distribution of the 
transfection complexes. After 24 hours cell medium was changed and the cells 
were grown for another 24-72 hours (according to individual experimental set-up) 
and successful gene silencing was documented on the mRNA and protein levels 
by quantitative RT-PCR and Western blotting. 
2.5.8 Collection of conditioned medium from MTAP silenced 
HCC cells 
For the purpose of studying potential effects of MTAP-deficient HCC on HSC 
cells in-vitro, transfection of HCC cells with MTAP siRNA was performed as 
described in 2.5.7. 24 hours after transfection HCC cells were washed twice with 
serum-free DMEM, and then incubated for 24 h with serum-free DMEM (1 ml per 
one well of a six-well plate) which was then collected and stored at -80° C until 
use. HCC cells transfected with negative control siRNA were used to generate 
control conditioned medium under otherwise identical conditions. 
2.6 Human tissues and HCC tissue microarray (TMA) 
Paired HCC and non-neoplastic liver tissues were obtained from HCC patients 
undergoing surgical resection in cooperation with the Center for Liver Cell 
Research, Department of Surgery, University Hospital Regensburg. Tissue 
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samples were immediately snap frozen and stored at -80°C until subsequent 
analysis. Human liver tissue was obtained and experimental procedures were 
performed according to the guidelines of the charitable state controlled 
foundation HTCR, with the informed patient's consent. 
The immunohistochemical results presented in this work are based on a tissue  
microarray, which was described before (111). Generally, in the tissue microarray 
technique, a hollow needle is used to remove small tissue cores from both 
cancerous and adjacent non-cancerous regions in paraffin-embedded tissues 
such as clinical biopsies. These tissue cores are then inserted in a recipient 
paraffin block in a precisely spaced, array pattern. Sections from this block are 
cut using a microtome, mounted on a microscope slide and then analyzed by any 
method of standard histological analysis 
For the presented HCC tissue microarray, immunohistochemical staining of 5-µm 
sections of the TMA blocks was performed using a monoclonal mouse anti-
human MTAP antibody (ab55517, abcam, Cambridge, UK) at a dilution of 1:500 
and an indirect immunoperoxidase protocol according to the LSAB2-kit (Dako, 
Hamburg, Germany). For negative control, the primary antibody was omitted and 
IgG isotype control antibodies did not reveal any detectable staining. For analysis 
of the tissue microarray, positivity for MTAP was defined as any detectable 
staining, while cases designated as MTAP negative did not reveal any 
immunohistochemical staining for MTAP.  
2.7 MTA extraction and analysis  
For analysis of MTA in cell culture medium, cells were cultured in serum free 
medium for 24 h. Subsequently, medium was collected, centrifuged, and the 
supernatant was snap-frozen and stored at -80°C. Further, cell number in 
corresponding cell culture plates was determined by counting the trypsinised 
cells. 
For intracellular MTA measurements, cells were harvested by incubation in a 
solution containing 0.05% (w/v) trypsin and 0.02% (w/v) EDTA. Trypsination was 
stopped after 5 min with cell culture medium. Following centrifugation, the 
supernatant was removed, the cell pellet was washed with PBS buffer, 
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centrifuged again, snap-frozen and stored at -80°C.  
Samples were further processed by the Institute of Functional Genomics, 
University of Regensburg, as described in greater detail in (112;113). Briefly, cell 
culture medium was spiked with stable isotope labeled MTA, dried by means of 
an infrared evaporator, and the residues reconstituted in 0.1 mol/L acetic acid. 
Frozen cell pellets were extracted by three repeated freeze/thaw cycles in 600 µL 
of MeOH / 0.1 mol/L acetic acid (80:20, v/v) after the addition of stable isotope 
labeled MTA. After centrifugation the supernatant was transferred in a glass vial 
and the protein pellet was washed twice with MeOH/acetic acid. The combined 
extracts were dried and reconstituted in 0.1 mol/L acetic acid. 
Tissue samples were weighed and then homogenized in 600 µL of MeOH/ 0.1 
mol/L aqueous acetic acid (80:20, v/v) using “Precelly-Keramik-Kit 1.4 mm” vials 
(Peqlab Biotechnologie GmbH, Erlangen, Germany). The samples were 
centrifuged at 9,000 g for 5min at 4°C. Subsequently, the supernatant was 
transferred to a 1.5 mL glass vial and the pellet was washed twice. After solvent 
evaporation, the residues were reconstituted in 0.1 mol/L acetic acid.  
Liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-
ESI-MS/MS) was carried out as described (113). The analysis was performed 
using an Agilent 1200 SL HPLC system (Böblingen, Germany) and a PE Sciex 
API 4000 QTrap mass spectrometer (Applied Biosystems, Darmstadt, Germany). 
An Atlantis T3 3 µm (2.1mm i.d.×150mm) reversed-phase column (Waters, 
Eschborn, Germany) was used. LC separation was carried out using a water-
acetonitrile gradient consisting of 0.1% acetic acid and 0.025% HFBA in both 
solvents at a flow-rate of 400 µL/min with an injection volume of 10 µL. The API 
4000 QTrap mass spectrometer was operated in positive mode and quantitative 
determination was performed with multiple reaction monitoring (MRM). 
2.8 Isolation and analysis of RNA 
2.8.1 RNA isolation and determination of RNA concentration 
RNA isolation was performed with the RNeasy® mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. The principle of RNA 
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isolation is based on the adsorption of RNA to hydrophilic silicon-gel membranes 
in presence of suitable buffer systems. Biological samples were first lysed and 
homogenized in the presence of a highly denaturing guanidine isothiocyanate 
containing buffer, which immediately inactivates RNases to ensure isolation of 
intact RNA. To homogenize tissue samples a hand-held rotor-stator homogenizer 
(Xenox Motorhandstück 2.35 with a Roti®-Speed-Rührer Ø 7 mm, Carl Roth, 
Karlsruhe, Germany) has been used. After lysis, ethanol has been added to 
provide ideal conditions for the binding of RNA to the silica-gel membranes. 
Contaminants have been washed away with suitable buffers before RNA was 
eluted in water and stored at -80 °C. The concentration of RNA was measured 
with the NanoDrop® ND-1000 UV/VIS spectrophotometer (Peqlab, Erlangen, 
Germany). 
2.8.2 Reverse transcription of RNA to cDNA 
Transcription of RNA to complementary DNA (cDNA) was conducted with the 
Reverse Transcription System Kit (Promega, Mannheim, Germany) which uses 
avian myeloblastosis virus reverse transcriptase (AMV RT). The working solution 
was pipetted with contamination-free aerosol filter pipet tips after the following 
pipetting scheme: 
 
0.5 µg  RNA 
5 µl   MgCl2 (25 mM) 
2.5 µl  10x reverse transcription buffer 
2.5 µl   dNTP mix (10 mM) 
1.25 µl  random primer 
0.625 µl  RNasin ribonuclease inhibitor 
ad 25 µl  H2Odest.
 
For reverse transcription the samples have been incubated in a GeneAmp® PCR 
cycler (Applied Biosystems, Foster City, USA) for 30 min at 42 °C. For 
denaturation of the AMV RT the temperature has been raised to 99 °C for 5 min. 
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After cooling down to 4 °C the obtained cDNA was diluted with 75 µl H2Odest. and 
used immediately or stored at -20 °C. 
2.8.3 Quantitative real time polymerase chain reaction 
To quantify the expression of specific mRNA, quantitative real time polymerase 
chain reaction (qRT-PCR) has been performed with the LightCycler II system 
(Roche Diagnostics, Mannheim, Germany). The qRT-PCR is principally based on 
a conventional polymerase chain reaction (PCR), but offers the additional 
possibility of quantification, which is accomplished by fluorescence 
measurements at the end and/or during a PCR cycle. As fluorescent reagent 
SYBR® Green (QuantiTect SYBR® Green PCR Kit, Qiagen, Hilden, Germany) 
has been used. SYBR® Green intercalates with double-strand DNA whereby the 
fluorescence emission rises significantly. Therefore, the fluorescence signal 
increases proportionally with the amount of PCR products. To quantify the 
expression of a specific gene of interest, the results have been normalized to the 
housekeeper gene β-actin for human samples and to 18s rRNA for murine 
samples, respectively. The results were evaluated with the LightCycler software 
version 3.5 (Roche Diagnostics, Mannheim, Germany) following the 
manufacturer’s instructions. The qRT-PCR was performed according to the 
QuantiTect® SYBR® Green PCR Master Mix protocol (Qiagen, Hilden, 
Germany): 
 
10 µl   QuantiTect® SYBR® Green PCR Master Mix  
2 µl    cDNA 
0.5 µl   forward primer (20 µM)  
0.5 µl   reverse primer (20 µM)  
7 µl   H2Odest.
 
The following standard scheme has been used and adapted to particular primer 
melting point temperature: 
 
Initial denaturation:   20 °C/s to 95 °C, 900 s  
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Three step PCR:   20 °C/s to 95 °C, 15 s 
     20 °C/s to 55-65 °C, 20 s, 40 cycles 
     20 °C/s to 72 °C, 20 s 
Analysis of melting curve:  20 °C/s to 95 °C, 0 s 
     20 °C/s to 65 °C, 15 s 
     0.1 °C/s to 95 °C, 0 s 
     20 °C/s to 40 °C, 30 s 
 
For validation, 5-10 µl of the PCR product has been mixed with loading buffer 
(Peqlab, Erlangen, Germany) and loaded on a agarose gel with ethidium bromide 
(50 μg/100 ml gel) to determine the PCR product length. Each experimental 
condition was performed in triplicates and experiments were repeated at least 
three times. 
Primers were synthesized by SIGMA Genosys (Hamburg, Germany). The 
lyophilized primers were solved in H2Odest. (SIGMA Genosys primers) and stored 
at -20 °C.  
2.8.4 Sets of primers used for quantitative PCR analysis 
name forward primer reverse primer 
β-actin 5’-CTA CGT CGC CCT GGA CTT CGA GC 5’-GAT GGA GCC GCC GAT CCA  CAC GG 
MTAP 5´- GCG AAC ATC TGG GCT TTG 5´- GCA  CCG GAG TCC TAG CTT C 
IL8 5’-TCT GCA GCT CTG TGT GAA GGT GCA GTT 5’- AAC CCT CTG CAC CCA  GTT TTC CT 
MMP-1 5´- TCA CCA AGG TCT CTG AGG GTC AAG C 5´- GGA TGC CAT CAA TGT CAT CCT GAG C 
MMP-9 5´- GAG GTG CCG GAT GCC ATT CAC GT 5´- CCG AGC TGA CTG GAC GGT GAT G 
MMP-14 5´- GGA ACC CTG TAG CTT TGT GTC TGT C 5´- TCT CTA CCC TCA AC AAG ATT AGA TTC C 
VEGFB 5´- TGG TGG TGC CCT TGA CTG TGG AGC 5´- CTG TCT GGC TTC ACA GCA CTG TCC 
FGF-2 5´- AGC CTA GCA ACT CTG CTG CTG ATG G 5´- ACG TAG GAG ACA CAG CGG TTC GAG 
 
Table 3: Primers for qRT-PCR. IL-8, interleukin 8; MMP, matrix metalloproteinase; 
VEGF, vascular-endothelial growth factor;  FGF-2, fibroblast growth factor 2. 
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2.9 Protein analysis 
2.9.1 Preparation of whole cell protein extracts 
Used buffer: 
RIPA buffer 50 mM  Tris/HCl; pH 7.5 
150 mM  NaCl 
1% (v/v) Nonidet® P40 
0.5% (w/v) Sodium desoxycholate 
0.1% (w/v) SDS  
 
To extract whole cell protein from cell lines the cell culture medium was 
discarded and cells were washed once with PBS, then scraped off with a cell 
scraper (Corning, NewYork, USA) and taken up into 1 ml of cooled PBS. After 
centrifugation (1,700 g, 5 min, 4 °C) the cell pellet was resuspended in 200 µl 
RIPA buffer and treated with an ultrasonoscope (Sonoplus hp 70, Bandelin 
electronics, Berlin, Germany) 10 x 3 s at an intensity of 40% for cell lysis. 
Subsequently, the solved proteins were separated from the non soluble cell 
components by centrifugation at 20,000 g (10 min, 4 °C). The protein solution 
was transferred into new reaction tubes and stored at -20 °C. 
2.9.2 Determination of protein concentration 
To determine the protein concentrations of protein solutions the BCA Protein 
Assay Kit (Pierce, Rockford, USA) was used. The assay combines the reduction 
of Cu2+ to Cu1+ by protein in an alkaline medium with the highly sensitive and 
selective colorimetric detection of the cuprous cation Cu1+ by bicinchoninic acid 
(BCA). The first step is the chelation of copper with protein in an alkaline 
environment to form a blue-colored complex. In this reaction, known as the biuret 
reaction, peptides containing three or more amino acid residues form a colored 
chelate complex with cupric ions in an alkaline environment. One cupric ion 
forms a colored coordination complex with four to six nearby peptides bonds. In 
the second step of the color development reaction, BCA, a highly sensitive and 
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selective colorimetric detection reagent reacts with the cuprous cation Cu1+ that 
was formed in step 1. The purple-colored reaction product is formed by the 
chelation of two molecules of BCA with one cuprous ion. The BCA/copper 
complex is water-soluble and exhibits a strong linear absorbance at 562 nm with 
increasing protein concentrations. 200 µl of alkaline BCA/copper(II) solution (50 
parts of solution A mixed with 1 part of solution B) was added to 2 µl of protein 
solution using a 96-well plate and have been incubated for 1 h at RT. Thereafter 
the purple color was measured at 562 nm with a spectrophotometer (EMax® 
Microplate Reader, MWG Biotech, Ebersberg, Germany). The optical 
absorbance values could be translated into specific protein concentrations by 
parallel quantification of a BSA standard. 
2.9.3 SDS polyacrylamid gel electrophoresis 
Used buffers: 
Laemmli buffer 62.5 mM Tris/HCl, pH 6.8 
2% (w/v) SDS 
10% (v/v) Glycerine 
5% (v/v) β-Mercaptoethanol 
 
Running buffer 25 mM Tris/HCl, pH 8.5 
200 mM Glycine 
0.1% (w/v) SDS 
 
10% Resolving gel 7.9 ml  H2Odest. 
5.0 ml  1.5 M Tris/HCl pH 8.8 
0.2 ml  10% (w/v) SDS 
6.7 ml  Acrylamide/Bisacrylamide 
  30%/0.8% (w/v) 
0.2 ml  Ammonium persulfate 
  10% (w/v) 
0.008 ml TEMED 
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5% Stacking gel 2.7 ml  H2Odest. 
0.5 ml  1.0 M Tris/HCl pH 6.8 
0.04 ml 10% (w/v) SDS 
0.67 ml Acrylamide/Bisacrylamide 
  (30%/0.8% w/v)  
0.04 ml Ammonium persulfate 
  10% (w/v) 
0.004 ml TEMED 
 
The protein solutions were heated at 95 °C for 5 min in Laemmli buffer and 
applied on a SDS polyacrylamid gel for protein fractionation by size at 
35 mA/150 V (XCell SureLock™ Mini-Cell, Invitrogen, Karlsruhe, Germany). As 
size marker the Full Range Rainbow Molecular Weight Marker (GE Healthcare, 
Freiburg, Germany) was used. 
2.9.4 Western blotting 
Used buffer: 
Transfer buffer 10% (v/v)  Methanol 
25 mM  Tris 
190 mM  Glycine 
 
 
To detect the proteins after SDS-PAGE by use of specific antibodies the proteins 
were transferred electrophoretically to a nitrocellulose membrane (Invitrogen, 
Karlsruhe, Germany) at 220 mA/300 V for 1.5 h (XCell II Blot Module, Invitrogen, 
Karlsruhe, Germany). To block unspecific binding sites, the membrane was 
bathed in PBS containing 3% BSA or 5% milk powder for 1 h at RT. Then, the 
membrane was incubated with a specific primary antibody (Table 4) over night at 
4 °C. After washing, the membrane was incubated with a secondary horseradish 
peroxidase (HRP) conjugated antibody (Table 4) for 1 h at RT.  
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Primary Antibody Manufacturing 
company 
Product # Dilution 
Mouse anti-human Actin  Sigma, Deisenhofen A1978 1:20,000 
Mouse anti-human MTAP  Abcam, Cambridge/UK abcam55517 1:3,000 
Secondary Antibody Manufacturing 
company 
Product # Dilution 
Goat anti-mouse HRP Santa Cruz, Heidelberg sc-47047 1:3,000 
 
Table 4:  Used primary and secondary antibodies for Western blot analysis; used 
dilution; manufacturing company. Secondary antibodies are conjugated with horseradish 
peroxidase (HRP) 
 
Thereafter, the membrane was washed with PBS and incubated with the ECL 
Plus Western Blotting Detection System (GE Healthcare, Freiburg, Germany) for 
1 min. This system utilizes chemiluminescence technology for the detection of 
proteins. It consists of the acridan substrate Lumigen PS-3, which is converted to 
an acridinium ester intermediate when catalyzed by HRP. The ester intermediate 
reacts with peroxide in alkaline conditions and emits light, which was detected by 
autoradiography using a Biomax film (Kodak, Stuttgart, Germany) and a Curix 60 
automatic film developer (Agfa, Cologne, Germany). All incubation steps were 
done on a KS 260 Basic Orbital Shaker (IKA®; Staufen, Germany). Western blot 
experiments were repeated at least three times. 
 
2.10 Cell-based functional assays 
2.10.1 XTT-proliferation assay 
Cell proliferation was quantified with the XTT kit (Roche Diagnostics, Mannheim, 
Germany). The assay is based on the ability of metabolic active cells to reduce 
the tetrazolium salt XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[phenylamino)carbonyl]-2H-tetrazolium hydroxide) to orange colored compounds 
of formazan. The dye formed is water soluble and dye intensity can be read with 
a spectrophotometer at a wavelength of 450 nm and a reference absorbance 
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wavelength of 650 nm. The intensity of the dye is proportional to the number of 
metabolic active cells.  
To quantify the effects of certain reagents on cell proliferation, cells were seeded 
in 96-well tissue culture plates (4,000 cells per well) and incubated for 4 h in 
medium containing 10% FCS. Thereafter, medium was taken off and cells were 
starved for 16 hours in FCS free medium. After a further medium change and 
addition of specific stimulatory reagents, cells were incubated for different time 
intervals (1-7 days). At the chosen time points XTT reagent was added and the 
intensity of the forming dye was measured two hours thereafter with an EMax 
Microplate Reader (MWG Biotech, Ebersberg, Germany). Values of optical 
density (OD) at individual time points were corrected for background by 
subtracting the OD value of a blank well without cells. Each experimental 
condition was performed in triplicate and experiments were repeated three times. 
 
2.11 Statistical analysis 
Values are presented as mean ± standard error (SEM). Comparisons between 
groups were made using the unpaired t-test (or one-way ANOVA with Bonferroni 
correction for more than 2 groups) or in the case of comparisons between 
HCC/non-HCC pairs using the paired t-test. Fisher's exact test was used to study 
the statistical association between clinicopathological and immunohistochemical 
variables. A p-value < 0.05 was considered statistically significant.  Calculations 
were performed using the statistical computer packages SPSS 15.0 and 
GraphPad Prism 9. 
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3 Results 
3.1 MTA concentration in human HCC cell lines and 
tissues 
Previously our group had shown that MTAP expression is strongly reduced in 
human HCC cell lines and tissues as compared to primary human hepatocytes 
(PHH) and non-tumorous tissue (62).  
One of the aims of this thesis was to analyze whether this downregulation of 
MTAP affected MTA levels in HCC. Liquid chromatography tandem mass 
spectrometry (LC-ESI-MS/MS) revealed significantly higher MTA levels in HCC 
as compared to non-tumorous liver tissue (Figure 7).  
 
 
Figure 7: MTA concentration in human HCC tissue. 
MTA levels in human HCC tissues (HCC) compared to adjacent 
non-tumorous liver tissues (non-HCC). 14 paired samples were 
analyzed. 
(*: P≤0.05 compared to non-HCC) 
 
Further, higher amounts of MTA were found in lysates of 4 different HCC cell 
lines as compared to PHH (Figure 8A).  
Levels of MTA were also higher in the corresponding supernatant of HCC cell 
cultures (Figure 8B).  
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Figure 8: MTA concentration in human HCC cell lines. 
MTA levels in cell lysates (A) and cell supernatants (B) of primary 
human hepatocytes (PHH) and the HCC cell lines PLC, HepG2, 
Hep3B and Huh-7. Cells were cultured for 24 h in FCS-free 
DMEM. 
 (*: P≤0.05 compared to PHH) 
 
 
To confirm that MTA accumulation in HCC cells is caused by downregulation of 
MTAP we analyzed HCC cells that had been transfected transiently with MTAP 
siRNA. MTAP suppression led to higher MTA concentrations both in cell lysates 
(Figure 9A) and in supernatants (Figure 9B).  
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Figure 9: Effect of MTAP suppression on MTA concentration in 
human HCC cells. 
The HCC cell line PLC was transiently transfected with negative control 
siRNA (si ctrl) or 2 different MTAP siRNAs (siMTAP1 and siMTAP2). 
MTA levels were measured in cell lysates (A) and supernatants (B) 48 h 
after transfection. 
(*: P≤0.05 compared to si ctrl). 
 
 
Corresponding successful MTAP suppression in the samples was documented 
on both MTAPsiRNA (Figure 10A) and protein (Figure 10B) levels. 
 
 
 
 38
 
Figure 10: MTAP suppression after transfection with MTAPsiRNA. 
MTAP mRNA (A) and protein (Western blot, B) expression in the cell 
samples from Figure 9. 
(*: P≤0.05 compared to si ctrl). 
 
3.2 MTA effects on HCC cells 
 
The functional effect of MTA on HCC cells was investigated by treating the HCC 
cell lines HepG2 and PLC with MTA doses similar to those determined in HCC 
tissue.  
Incubation with MTA led to a dose-dependent induction of the proliferation of 
HCC cells (Figure 11).  
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Figure 11: MTA effect on proliferation of HCC cells. 
Proliferation of the HCC cell line HepG2 after stimulation with MTA at 
different concentrations (0.05, 0.5 and 5 µmol/L) compared to 
untreated control cells (ctrl).   
 
Moreover, we analyzed the effect of MTA on the expression of several genes 
known to correlate with HCC progression and aggressiveness.  
Thus MTA induced IL8 (MIM 146930, Figure 12) expression. 
 
 
Figure 12: MTA effect on IL-8 expression of HCC cells. 
IL-8 mRNA expression of PLC cells after treatment (24h) with MTA at 
different concentrations (0.05, 0.5 and 5 µmol/L) compared to untreated 
control cells (ctrl).   
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Likewise, the expression of the matrix-metalloproteinases MMP1 (MIM120353), 
and MMP9 (MIM 120361) was also induced (Figure 13A and Figure 13B, 
respectively). 
 
 
 
 
Figure 13: MTA effect on MMPs expression of HCC cells. 
MMP-1 (A) and MMP-9 (B) mRNA expression of PLC cells after 
treatment (24h) with MTA at different concentrations (0.05, 0.5 and 5 
µmol/L) compared to untreated control cells (ctrl).   
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3.3 MTA effects on activated HSC 
Since down-regulation of MTAP in HCC also led to higher extracellular MTA 
levels, we investigated whether MTA also exerted an effect on stromal cells. 
Here, we focused on activated hepatic stellate cells (HSC). These myofibroblast-
like cells are located around tumor sinusoids and fibrous septa, and infiltrate the 
HCC stroma (114;115). Quantitative RT-PCR analysis revealed that incubation of 
HSC with MTA induced the expression of the MMP1 (Figure 14A) and FGF2 
(MIM 134920) genes (Figure 14B). 
 
Figure 14: MTA effect on activated HSC. 
MMP1 (A) and FGF2 (B) mRNA expression in activated hepatic stellate 
cells (HSC) after treatment (24 h) with MTA at different concentrations 
(0.05, 0.5 and 5 µmol/L) compared to untreated control cells (ctrl). 
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Notably, MMP1 and FGF-2 expression levels had been found to correlate with 
HCC progression (116;117). 
Furthermore, HSC were incubated with conditioned media (CM) collected from 
HCC cells transiently transfected with MTAP-siRNA or control-siRNA, 
respectively (see Figure 10). CM from HCC cells with suppressed MTAP gene 
expression induced significantly higher MMP1 and FGF2 gene expression than 
CM derived from HCC cells transfected with control-siRNA (Figure 15). 
 
 
Figure 15: Effect of conditioned medium derived from HCC on 
activated HSC. 
MMP1 (A) and FGF2 (B) mRNA expression in HSC after stimulation (24 
h) with conditioned media derived from PLC cells in which MTAP 
expression was depleted by transfection with MTAP siRNA (siMTAP1 
and siMTAP2) or from PLC cells transfected with control siRNA (si ctrl). 
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These findings indicate that downregulation of MTAP and consecutive elevation 
of intracellular and extracellular MTA levels promotes tumorigenesis of HCC cells 
directly as well as indirectly via induction of pro-cancerous genes in stromal cells. 
 
3.4 MTAP expression in human HCC tissue 
 
To further evaluate the functional effects of MTAP downregulation in HCC in vivo 
we analyzed MTAP protein expression in a series of 140 human HCC tissues 
applying tissue microarray (TMA) technology. In 57 HCCs (40.7%) 
immunohistochemistry revealed no MTAP immunosignal. In contrast, MTAP 
expression was visible in all non-tumorous tissue (data not shown), which 
confirms that in a considerable portion of human HCC MTAP protein expression 
is significantly downregulated or lost, respectively.  
For descriptive data analysis, HCC were separated into tissues with positive and 
negative MTAP immunosignal (representative examples are depicted in Figure 
16A). Matched data of mRNA expression and semiquantitative protein 
expression analyzed on the TMA were available from 25 HCC patients. MTAP 
mRNA expression was significantly higher in HCC cases with positive MTAP 
immunosignal (n=15) compared to cases, where no MTAP was detectable (n=10; 
Figure 16B). This finding indicates that MTAP expression is accurately detected 
by immunohistochemistry. 
A correlation of immunohistochemical results with clinico-pathological tumor 
characteristics (Table 5) revealed that loss of MTAP expression was significantly 
associated with higher tumor stage (P=0.032) and tumor grading (P=0.019). No 
correlation was found between MTAP expression and age, gender or tumor size. 
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Figure 16: MTAP expression in human HCC tissue. 
(A) Representative MTAP immunohistochemical (IH) staining results of 
HCC tissue samples arranged on a tissue microarray (left panel: MTAP 
negative; right panel: MTAP positive).  
(B) MTAP mRNA expression in 10 HCC tissues with negative and 15 
HCC tissues with positive MTAP immunohistochemical staining (IH). 
(*: P≤0.05 compared to MTAP IH negative). 
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Variable        MTAP IR MTAP IR
  Categorization n %  negative positive 
P* 
          
Clinicopathological characteristics      
Age at diagnosis        
  <60 years 52 37.1  17 35 0.157 
  ≥60 years 88 62.9  40 48  
Gender        
  female 21 15.0  10 11 0.483 
  male 119 85.0  47 72  
Tumor stage       
  pT1 47 33.6  13 34 0.032 
  pT2 42 30.0  15 27  
  pT3 46 32.9  25 21  
  pT4 3 2.1  2 1  
  nd 2 1.4     
Histological grade       
  G1 53 37.9  15 38 0.019 
  G2 70 50.0  31 39  
  G3 17 12.1  11 6  
Tumor size       
  ≤ 5 cm 70 50.0  23 47 0.339 
  > 5 cm 40 34.3  20 28  
  nd 30 15.7     
 
Table 5: MTAP immunoreactivity (IR) in HCC-tissue of 140 patients in 
relation to clinicopathological characteristics 
* Fisher's exact test (2-sided); bold face representing P-values ≤0.05. 
(nd: no data available; IR: immunoreactivity)  
 
From HCCs on the TMA no suitable tissue samples for MTA analysis were 
available. However, analysis of HCC specimens from another 19 patients 
revealed an inverse correlation between MTAP mRNA expression and MTA 
levels (r= -0.46; P= 0.047; Figure 17). 
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Figure 17: Correlation of MTA levels with MTAP mRNA expression  
in human HCC tissue. 
Data are based on 19 human HCC samples showing a significant 
(p=0.047) inverse correlation of medium size (Pearson´s r=-0.46). 
 
In summary, these data indicate that also in vivo MTAP downregulation leads to 
increased MTA levels, which functionally affect HCC progression.  
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4 Discussion 
In a previous study by our group it was shown that downregulation of MTAP in 
HCC cell lines enhanced tumorigenicity in vitro (62). Due to the lack of a 
sensitive detection method, it was not possible to determine at that time the 
amounts of MTA in or secreted by HCC cells, and thus, the molecular 
mechanism for the tumor-promoting effect of MTAP deficiency in HCC remained 
unsolved. A later study examining MTAP expression in malignant melanoma 
using LC-ESI-MS/MS to measure MTA found an elevation of MTA levels in skin 
cancer sell lines and tumor samples (88). We speculated that similar changes 
might be found in HCC and indeed we could show that cell media as well as 
intracellular MTA levels were significantly higher in 4 different HCC cells than in 
primary hepatocytes. Experimental inhibition of MTAP expression in HCC lines 
with 2 siRNAs caused inverse changes of MTA levels, indicating that enhanced 
MTA levels in HCC were caused by downregulation of MTAP. 
The difference in MTA concentrations between HCC cell lines and primary 
hepatocytes was more pronounced in the cell media than intracellularly which is 
line with the finding that tumor MTAP deficient cells are able to excrete MTA 
indicating that MTAP deficiency is likely to influence not only intracellular 
processes but also the hepatocytes´ environment (63;66;118). 
Importantly, this study found an induction of the gene expression of MMP1, 
MMP9, and IL8 upon treatment of HCC cells with MTA in doses similar to those 
found in vivo in HCC. The increased expression of these genes is a well 
documented event in hepatocarcinogenesis and correlates with various more 
aggressive clinicopathological HCC features, specifically with invasive potential 
(116;119). It was previously shown that MTAP over-expressing HCC cells in 
culture have reduced invasive potential (62) and it may now be speculated that in 
MTAP-deficient HCC cells, MTA-induced up-regulation of MMP1 and 9 is at least 
one of the underlying mechanisms. 
Moreover, effects of MTA were not only observed in the tumor cells, but also in 
activated HSC that constitute an important cellular component of the tumor 
microenvironment. They are located around tumor sinusoids, fibrous septa and 
 
 48
capsule, if the latter is present (114;115)  and recently, in our group it was shown 
that activated HSC promote tumorigenicity of HCC (6). Thus, the observed up-
regulation of MMP1 and FGF2 by HSC caused by MTA stimulation is of 
importance, because in addition to MMP1, FGF2 is an important angiogenic 
factor shown to be associated with the capsular  infiltration of HCC (119), with 
more invasive HCCs (117) and also with enhanced proliferation of HCC cells in 
vitro (120). Further, similar MTA induced gene expression changes are found in 
melanoma cells as well (88) which supports that these MTA induced effects are 
possibly not confined to the liver but may be common to many malignant cells.  
Together these findings indicate that the tumor-promoting effect of MTAP 
deficiency in HCC is at least in part mediated by enhanced MTA levels. 
Most importantly, this study could demonstrate the clinical relevance of MTAP 
downregulation in HCC. Although MTAP deficiency is documented in various 
human malignancies, only a few studies (and none on HCC) include a 
representative number of tumor samples to assess its frequency and possible 
clinical significance. Already previously, our group found lower MTAP mRNA and 
protein expression in a limited number of HCC tissue samples compared to 
adjacent non-cancerous tissue (62). Here, we confirmed downregulation of 
MTAP in a significant number of human HCCs, and most strikingly, MTAP 
deficiency correlated with more advanced tumor staging and poorer 
histopathological grading.  
Remarkably, also in human HCC tissue MTAP expression correlated inversely 
with MTA levels, suggesting that also in vivo enhanced MTA levels account at 
least to a certain extent for the tumor promoting effect of MTAP deficiency. 
Studies by others revealed that MTA exhibited an anti-inflammatory activity on 
macrophages and lymphocytes, thus, further supporting a direct tumor-promoting 
effect of MTA (121-123). 
In contrast to our findings, some groups have reported pro-apoptotic effects of 
MTA on hepatoma cells, and inhibitory effects on proliferation and invasion of 
various cell lines as well as differentiation and growth factor receptor activation 
(71;104;124-127). However, in most of those studies significantly higher, 
pharmacological doses had been administered, whereas the MTA levels 
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achieved here mirrored endogenous tumor levels. In addition, the therapeutic 
effect of MTA seems to be dependent on the cell type and the MTAP level in the 
cells (128). Further, in line with our results, previous studies suggested a 
correlation of MTAP deficiency with poor differentiation in non-Hodgkin’s 
lymphoma (129). In contrast, in a large lung cancer study (73) this association 
was not observed showing that the role of MTAP deficiency in tumor progression 
is likely tumor-specific.  
In conclusion, we demonstrated that the downregulation of MTAP in HCC leads 
to increased MTA levels, which functionally affect cancerous cells as well as 
tumor stromal cells in a tumor supportive way. This work advances MTAP as a 
tumor suppressor in HCC, and MTA as potential biomarker for the progression of 
this highly aggressive tumor. 
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6 Appendix 
6.1 Zusammenfassung (deutsch) 
Titel: Die verminderte Expression von Methylthioadenosin-phosphorylase fördert 
das Fortschreiten des hepatozellulären Karzinoms über eine Anhäufung von 5´-
deoxy-5´-methylthioadenosin  
Einführung: Das hepatozelluläre Karzinom (HCC) nimmt weltweit den dritten 
Platz  unter den  krebsbedingten Todesursachen ein. Die häufigsten 
Risikofaktoren für die HCC Entstehung sind chronische Hepatitis B und C 
Infektion sowie chronischer Alkoholabusus, die zu einer Leberzirrhose führen. 
Weniger bekannt ist jedoch die molekulare Pathogenese des HCC. Viele 
genomische Veränderungen im HCC Verlauf sind bereits beschrieben worden 
aber ihre funktionelle Bedeutung und genaue Rolle für das Fortschreiten des 
HCC bleiben in vielen Fällen noch unklar.  
Vor kurzem wurde eine verminderte Expression der Methylthioadenosin- 
phosphorylase (MTAP) in HCC Zelllinien beschrieben. MTAP  spielt eine 
Schlüsselrolle im Polyaminmetabolismus und stellt den geschwindigkeits-
bestimmende Schritt in der Wiedergewinnung von Methionin und Adenin dar. 
Ziele der Arbeit waren die Untersuchung der klinisch-pathologischen Bedeutung 
der Herabregulation von MTAP im HCC und die Erforschung der Mechanismen, 
die der pro-tumorigenen Wirkung der MTAP-Defizienz im HCC zugrundeliegen. 
Methoden and Ergebnisse:  Sowohl intrazellulär als auch in Überständen von 4 
HCC-Zellinien fanden sich im Vergleich zu primären humanen Hepatozyten 
signifikant erhöhte 5´-deoxy-5´-methylthioadenosin (MTA) Konzentrationen, 
welche durch stabile Isotopenverdünnungsanalyse bestimmt wurden. Weiterhin 
führte eine Suppression der MTAP-Expression in vitro in HCC Zellen mittels 
siRNA zu erhöhten MTA Spiegeln. Ferner induzierte MTA in HCC-Zellen die 
Expression von Matrixmetalloproteinasen (MMPs) und IL-8 sowie deren 
Proliferation. In aktivierten hepatischen Sternzellen, die aus humanem HCC 
Gewebe isoliert wurden, induzierte MTA die mRNA Expression von MMP1 und 
Fibroblast-Growth Factor 2 (FGF-2).  
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Die immunohistochemische Analyse von einem Gewebemicroarray von 140 
humanen HCC Proben zeigte eine signifikante Korrelation zwischen verminderter 
MTAP Proteinexpression und fortgeschritteneren histopathologischen HCC-
Stadien bzw. schlechterer Tumordifferenzierung. Weiterhin zeigte sich auch in 
vivo in 19 humanen HCC Proben ein signifikanter Zusammenhang zwischen 
verminderter MTAP-Expression und erhöhten MTA Spiegeln. 
Diskussion: Eine verminderte MTAP Expression im HCC fördert die 
Tumorigenität über eine Anhäufung von MTA. MTA beeinflusste sowohl HCC 
Zellen als auch die Tumorumgebung. Die Arbeit zeigt, dass MTAP im HCC einen 
Tumorsuppressor darstellt. 
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